Protocol Ledger

NCT07028697 · Phase III · COMPLETED

A Study to Evaluate the Efficacy and Safety of Daridorexant in Participants With Insomnia Disorder

Interventional Phase III clinical trial protocol NCT07028697 sponsored by Nxera Pharma Korea Co in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-12-04 Enrollment: 164 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT07028697
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)164 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07028697
Protocol FieldVerified Registry Value
NCT IdentifierNCT07028697
Consolidated Lead SponsorNxera Pharma Korea Co
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment164 participants (ACTUAL)
Registered Start Date2024-12-04
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07028697
Hospital Research SiteLocationSite Profile
Chungnam National University HospitalDaejeon, South KoreaOpen Hospital Dossier ->
Chonnam National University HospitalGwangju, South KoreaOpen Hospital Dossier ->
Gachon University Gil Medical CenterIncheon, South KoreaOpen Hospital Dossier ->
Seoul National University Bundang HospitalSeongnam-si, South KoreaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI